As Originally Reported Under Asc 605 was Wave Life Sciences’s largest revenue line in fiscal 2017, bringing in $3.70M of $3.89M (95%).
| Initial Application Period Cumulative Effect Transition | FY 2016 | FY 2017 |
|---|---|---|
| As Originally Reported Under Asc 605 | $1.49M | $3.70M |
| Effect Of Change | -$393.00K | $189.00K |
| Total | $1.09M | $3.89M |
Wave Life Sciences brought in $3.89M from its two revenue lines in fiscal 2017, the year ended December 31, 2017. That was up 256.5% from $1.09M in fiscal 2016. As Originally Reported Under Asc 605 was the largest at $3.70M (95.1%), ahead of Effect Of Change at $189.00K (4.9%).
Wave Life Sciences (WVE) reports its revenue by initial application period cumulative effect transition. In fiscal 2017, As Originally Reported Under Asc 605 was its largest revenue line, bringing in $3.70M (95.1% of the total), followed by Effect Of Change at $189.00K (4.9%).
As Originally Reported Under Asc 605 was Wave Life Sciences' largest revenue line in fiscal 2017, bringing in $3.70M, or 95.1% of the $3.89M total across its two revenue lines.
Every figure comes from Wave Life Sciences' annual financial filings, as reported. Each line keeps the name Wave Life Sciences gives it, and years follow its fiscal calendar.
Wave Life Sciences' revenue by initial application period cumulative effect transition goes back to fiscal 2016, with figures through fiscal 2017. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.